Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Bayne

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Pharmaceutical Sciences|October 1, 1977
Dosage form index: an objective criterion for evaluation of controlled-release drug delivery systemsF Theeuwes, W Bayne
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 1, 1978
Gastrointestinal therapeutic system for acetazolamide. Efficacy and side effectsF Theeuwes, W Bayne, J McGuire
Journal of Pharmaceutical Sciences|November 1, 1993
In vivo evaluation of controlled-release productsS S Hwang, W Bayne, F Theeuwes
European Urology|May 15, 1999
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancerF K Habib, M Ross, C W Bayne
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Induction of 5alpha-reductase type II mRNA transcription in primary cultured prostate epithelial cells by a soluble factor produced by primary cultured prostate fibroblast cellsC W Bayne, M Ross, N F Inglis
Journal of Chromatography|April 22, 1970
Autotransfer chromatography combined with mass spectroscopy, for the characterization of pyrroles and indolesD G Irvine, W Bayne, J R Majer
Journal of Pharmaceutical Sciences|October 1, 1978
Pharmacokinetics of drug permeation through human skinS K Chandrasekaran, W Bayne, J E Shaw
The Prostate. Supplement|November 1, 2000
Development of a new in vitro model for the study of benign prostatic hyperplasiaF K Habib, M Ross, C W Bayne
Veterinary Immunology and Immunopathology|May 9, 2006
Contribution of respiratory burst activity to innate immune function and the effects of disease status and agent on chemiluminescence responses by ruminant phagocytes in vitroJ C Hodgson, C A Watkins, C W Bayne
The Prostate|July 27, 1999
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPHC W Bayne, F Donnelly, M Ross, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Pharmaceutical Sciences|October 1, 1977
Dosage form index: an objective criterion for evaluation of controlled-release drug delivery systemsF Theeuwes, W Bayne
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 1, 1978
Gastrointestinal therapeutic system for acetazolamide. Efficacy and side effectsF Theeuwes, W Bayne, J McGuire
Journal of Pharmaceutical Sciences|November 1, 1993
In vivo evaluation of controlled-release productsS S Hwang, W Bayne, F Theeuwes
European Urology|May 15, 1999
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancerF K Habib, M Ross, C W Bayne
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Induction of 5alpha-reductase type II mRNA transcription in primary cultured prostate epithelial cells by a soluble factor produced by primary cultured prostate fibroblast cellsC W Bayne, M Ross, N F Inglis
Journal of Chromatography|April 22, 1970
Autotransfer chromatography combined with mass spectroscopy, for the characterization of pyrroles and indolesD G Irvine, W Bayne, J R Majer
Journal of Pharmaceutical Sciences|October 1, 1978
Pharmacokinetics of drug permeation through human skinS K Chandrasekaran, W Bayne, J E Shaw
The Prostate. Supplement|November 1, 2000
Development of a new in vitro model for the study of benign prostatic hyperplasiaF K Habib, M Ross, C W Bayne
Veterinary Immunology and Immunopathology|May 9, 2006
Contribution of respiratory burst activity to innate immune function and the effects of disease status and agent on chemiluminescence responses by ruminant phagocytes in vitroJ C Hodgson, C A Watkins, C W Bayne
The Prostate|July 27, 1999
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPHC W Bayne, F Donnelly, M Ross, et al.
Pageof 3